Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,041 to 1,060 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Pan-Cancer Proteomics Analysis to Identify Tumor-Enriched and Highly Expressed Cell Surface Antigens as Potential Targets for Cancer Therapeutics. | Mol Cell Proteomics | 2023 | 37517589 | PubTator, text mining | PubMed |
| Prognostic significance of trophoblastic cell surface antigen 2 expression and pathologic parameters in patients with ampullary adenocarcinoma. | Hum Pathol | 2023 | 37516386 | PubTator, text mining | PubMed |
| Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. | Pharmaceutics | 2023 | 37513983 | PubTator, text mining | PubMed |
| Pesticides and Bladder Cancer: Mechanisms Leading to Anti-Cancer Drug Chemoresistance and New Chemosensitization Strategies. | Int J Mol Sci | 2023 | 37511154 | PubTator, text mining | PubMed |
| Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging. | Biomedicines | 2023 | 37509725 | PubTator, text mining | PubMed |
| Upper Tract Urothelial Carcinoma: A Rare Malignancy with Distinct Immuno-Genomic Features in the Era of Precision-Based Therapies. | Biomedicines | 2023 | 37509415 | PubTator, text mining | PubMed |
| The 2EF Antibody Targets a Unique N-Terminal Epitope of Trop-2 and Enhances the In Vivo Activity of the Cancer-Selective 2G10 Antibody. | Cancers (Basel) | 2023 | 37509383 | PubTator, text mining | PubMed |
| Promising Highly Targeted Therapies for Cholangiocarcinoma: A Review and Future Perspectives. | Cancers (Basel) | 2023 | 37509347 | PubTator, text mining | PubMed |
| Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium. | J Hematol Oncol | 2023 | 37507780 | PubTator, text mining | PubMed |
| Immunohistochemical Expression of HBME-1 and TROP-2 in Some Follicular-Derived Thyroid Lesions. | Asian Pac J Cancer Prev | 2023 | 37505760 | PubTator, text mining | PubMed |
| An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer. | Medicine (Baltimore) | 2023 | 37505137 | PubTator, text mining | PubMed |
| Antibody-Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond-A 2023 Review. | Curr Oncol | 2023 | 37504334 | PubTator, text mining | PubMed |
| Therapeutic resistance to anti-oestrogen therapy in breast cancer. | Nat Rev Cancer | 2023 | 37500767 | PubTator, text mining | PubMed |
| Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens. | Front Oncol | 2023 | 37492478 | PubTator, text mining | PubMed |
| Advances and Prospects in the Treatment of Pancreatic Cancer. | Int J Nanomedicine | 2023 | 37489138 | PubTator, text mining | PubMed |
| Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. | Nat Med | 2023 | 37488289 | PubTator, text mining | PubMed |
| Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin. | Cancer Manag Res | 2023 | 37485038 | PubTator, text mining | PubMed |
| Targeting Mcl-1 by a small molecule NSC260594 for triple-negative breast cancer therapy. | Sci Rep | 2023 | 37481672 | PubTator, text mining | PubMed |
| Nectin-4 is frequently expressed in primary salivary gland cancer and corresponding lymph node metastases and represents an important treatment-related biomarker. | Clin Exp Metastasis | 2023 | 37480387 | PubTator, text mining | PubMed |
| Platform-agnostic CellNet enables cross-study analysis of cell fate engineering protocols. | Stem Cell Reports | 2023 | 37478860 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=53